Introduction Dopamine-mediated neurotransmission is important in many physiological functions, such as control of motor behaviour, learning, cognition, motivated behaviours and hormone production. Clinical evidences suggest that dopaminergic pathways are involved in several neurological and psychiatric disorders [1] . For example, a gradual loss of midbrain dopamine-producing cells results in extensive dopamine depletion in the striatum and the characteristic motor symptoms observed in Parkinson's disease: bradykinesia, rigidity, resting tremors and postural instability. The main treatment for Parkinson's disease is based on dopamine replacement using L-dopa, a precursor for the biosynthesis of endogenous dopamine. At the other end of the dopamine pathology spectrum, hyperactivity of the mesolimbic dopaminergic system is thought to be a prominent driving force in the pathophysiology of schizophrenia. This hypothesis is based on the fact that the antagonism of the D 2 class of dopamine receptors is an essential prerequisite for the therapeutic efficacy of antipsychotic medications [2] . Dopamine neurotransmission is also deeply involved in drug addiction. The mesolimbic dopaminergic system, comprising dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and their projections to the nucleus accumbens and prefrontal cortex, is the most important mediator of drug reward [3] . It is generally believed that drugs of abuse usurp the functioning of this neural circuitry, which normally controls responses to natural rewards, such as food, sex and social interactions.
The effects of dopamine are mediated by its interaction with G-protein-coupled membrane receptors. The dopamine receptor family contains five members in two subfamilies: the D 1 -like family, which includes D 1 and D 5 receptors; and the D 2 -like family, which includes D 2 , D 3 and D 4 receptors (reviewed in Ref. [4]). However, changes in dopamine neurotransmission are short-lived and therefore unlikely, by themselves, to account for behavioural changes that are long lasting. Transient and reversible modulation of signal transduction molecules such as kinases (as follows neurotransmitter receptor activation) is converted into long-lasting changes at the molecular and cellular levels by transcription factors. These factors, which are encoded by a vast family of genes, in turn modulate the expression of target genes. They are important during brain development, and in neurons they actively participate in adaptive responses following changes in the environment such as ischemia, lesion, denervation or exposure to drugs that affect neurotransmitter systems [5] . Activation of immediate-early genes (IEGs) constitutes one of the initial steps of the mechanisms by which stimuli at the cell membrane are transduced into short-term and long-term neuronal responses [6] . In recent years, data have emerged to suggest that transcription factors of the Nur and retinoid X receptor (RXR) subgroups have an important role in dopamine-mediated effects. In this review, we describe recent literature indicating that Nur77 and RXR factors work in concert as adaptive and homeostatic regulators of dopamine function in the context of dopamine-related psychiatric and neurological disorders. Based on current knowledge, we would like to propose a model in which Nur77 has a key role as a molecular switch in dopamine-related neuroadaptation processes.
Nurs are versatile transcription factors that have multiple functions in the periphery Nurs are part of the nuclear hormone receptor superfamily. They are defined as the orphan NR4A subgroup, which includes Nur77 (also known as NR4A1 and as nerve growth
